Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$0.94−0.09 (-8.75%)
Close on Nov 19, 2026Market cap $88.09MP/E –Yield –
Innate Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -€52.90M. The highest annual figure on record is €33.65M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€52.90M | – |
| FY2024 | Dec 31, 2024 | -€7.29M | – |
| FY2023 | Dec 31, 2023 | -€32.91M | – |
| FY2022 | Dec 31, 2022 | -€19.69M | – |
| FY2021 | Dec 31, 2021 | -€59.39M | – |
| FY2020 | Dec 31, 2020 | -€52.67M | -256.5% |
| FY2019 | Dec 31, 2019 | €33.65M | – |
| FY2018 | Dec 31, 2018 | -€33.40M | – |
| FY2017 | Dec 31, 2017 | -€51.02M | – |
See a number that looks wrong?